Loading
A phase 3 trial in lung cancer, run by Second Affiliated Hospital, Zhejiang University, School of Medicine, now recruiting.
Stereotactic Body Radiotherapy for Oligo-Progression Metastatic Non-Small Cell Lung Cancer is a phase 3, randomised interventional study registered as NCT06523673 by Second Affiliated Hospital, Zhejiang University, School of Medicine, with a registry enrolment figure of 104 participants, started 2024-09 and due to reach its primary completion in 2027-09. Interventions recorded: Stereotactic Body Radiotherapy; second-line systemic therapy. Conditions listed: Metastatic Non-Small Cell Lung Cancer; NSCLC Stage IV; OligoProgressive Metastatic Disease. Primary outcome: progression-free survival (PFS). Lung eligibility wording from the registry: "* Histologically and/or cytologically confirmed stage IV metastatic NSCLC". Sites: China. No results are recorded here; the registry entry is the source.
Shares SBRT / SABR (stereotactic radiotherapy), Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares SBRT / SABR (stereotactic radiotherapy), Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares SBRT / SABR (stereotactic radiotherapy), Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.